Cargando…
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection
Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are currently no prophylactic vaccines. In this study, we designed in silico a synthetic recombinant vaccine against visceral leishmaniasis (VL) called ChimeraT, which contains specific T-cell epitopes from...
Autores principales: | Lage, Daniela P., Ribeiro, Patrícia A. F., Dias, Daniel S., Mendonça, Débora V. C., Ramos, Fernanda F., Carvalho, Lívia M., de Oliveira, Daysiane, Steiner, Bethina T., Martins, Vívian T., Perin, Luísa, Machado, Amanda S., Santos, Thaís T. O., Tavares, Grasiele S. V., Oliveira-da-Silva, João A., Oliveira, Jamil S., Roatt, Bruno M., Machado-de-Ávila, Ricardo A., Teixeira, Antônio L., Humbert, Maria V., Coelho, Eduardo A. F., Christodoulides, Myron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426426/ https://www.ncbi.nlm.nih.gov/pubmed/32821440 http://dx.doi.org/10.1038/s41541-020-00224-0 |
Ejemplares similares
-
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection
por: Lage, Daniela P., et al.
Publicado: (2022) -
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
por: Lage, Daniela P., et al.
Publicado: (2020) -
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
por: Costa, Rafaella R., et al.
Publicado: (2021) -
Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis
por: Freitas, Camila S., et al.
Publicado: (2020) -
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection
por: Galvani, Nathalia C., et al.
Publicado: (2021)